Summit Therapeutics price to book ratio SMMT

Market value divided by the book value of the company's net assets, since 2020.

Today, Oct 23, 2026: 19.6×
6-year median: 15.3×
Against its 6-year history: 57th; percentile: 0 is its lowest day, 100 its highest
6-year range: 1.2× to 183×
Peer median: 7.7×

Summit Therapeutics' price to book ratio is 19.6× as of Oct 23, 2026.

That is above its 6-year median of 15.3×, close to the middle of its last 6 years.

Over that time it ranged from 1.2× in Dec 2022 to 183× in Jul 2024.

The median for 10 large drugmakers of a similar size is 7.7×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	19.6×	16.5×	76.2×
2025	70.2×	30.1×	76.4×
2024	30.7×	18.0×	183×
2023	18.4×	2.3×	18.4×
2022	6.4×	1.2×	6.4×
2021	2.6×	2.6×	20.0×
2020	10.5×	9.7×	12.7×

Against its peers

Companies in Drug Manufacturers - General nearest Summit Therapeutics' size, closest first, today.

Company	Price to book ratio
SMMTSummit Therapeutics	19.6×
JAZZJazz Pharmaceuticals	2.9×
BMRNBiomarin Pharmaceutical	1.7×
CORTCorcept Therapeutics	13.2×
PTGXProtagonist Therapeutics	10.6×
TGTXTG Therapeutics	13.7×
ALKSAlkermes plc.	4.0×
AMRXAmneal Pharmaceuticals	197×
LGNDLigand Pharmaceuticals	6.3×
KNSAKiniksa Pharmaceuticals International	9.2×
BIIBBiogen	2.0×
Peer median	7.7×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Summit Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.